Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071263 · ClinicalTrials.gov registry record · Phase 2
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
A Phase 2 study, sponsored by Relypsa.
- Completed
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
NCT03071263 is a Phase 2 study that has completed, run by Relypsa. The registered enrollment target is 295 participants.
The verdict
NCT03071263, a Phase 2 study, has completed, sponsored by Relypsa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure control compared with treatment with spironolactone alone (placebo).
Interventions
- DRUG Placebo
- DRUG Spironolactone
- DRUG Patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2018-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03071263
The ClinicalTrials.gov registry entry for NCT03071263 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Relypsa, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03071263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03071263 about?
NCT03071263 is a clinical study titled "Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease". The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure c...
What is the current status of trial NCT03071263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2017-01-23. Estimated completion is 2018-11-27.
What interventions are being tested in trial NCT03071263?
The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG), Patiromer (DRUG).
Who is sponsoring clinical trial NCT03071263?
This trial is sponsored by Relypsa, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.